Effect of MP-AzeFlu, FP + LOR and placebo on nasal symptoms. Data are presented as mean change from baseline in total nasal symptom score (TNSS) assessed over a period of 4 h following exposure to ragweed pollen in an allergen exposure chamber. Arrow: onset of action; dotted arrow: onset to clinically relevant effect compared to placebo (i.e. 1.17 change in TNSS). MP-AzeFlu (MP-azelastine/fluticasone propionate; Dymista®; 1 spray/nostril; 138 μg/50 μg); FP (fluticasone propionate; Flonase®; 1 spray/nostril; 50 μg) + LOR (Loratadine; Claritin®; 10 mg). LS: least squares; SE: standard error. *p ≤ 0.005 vs placebo; †p = 0.038 vs placebo; ‡p ≤ 0.003 vs FP + LOR.